EU’s Need For Digitalization Under Spotlight Again
Medicines For Europe Calls For Interconnected Digital Regulatory Infrastructure By 2022
Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic.
You may also be interested in...
EU Industry Sets Out Priorities In Structured Dialog
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.
EU Pharma Strategy Offers Window For Regulatory Optimization
Attendees to Medicines for Europe’s Regulatory Affairs and Pharmacovigilance virtual conference heard that a window of opportunity to optimize the region’s regulatory landscape is now “wide open” with the advent of the new EU Pharmaceutical Strategy.
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.